In vitro susceptibility to posaconazole of 1,903 yeast isolates recovered in France from 2003 to 2006 and tested by the method of the European committee on antimicrobial susceptibility testing

Olivier Lortholary; Eric Dannaoui; Dorothée Raoux; Damien Hoinard; Annick Datry; André Paugam; Jean-Louis Poirot; Claire Lacroix; Françoise Dromer; YEASTS Group

doi:10.1128/AAC.00496-07

In vitro susceptibility to posaconazole of 1,903 yeast isolates recovered in France from 2003 to 2006 and tested by the method of the European committee on antimicrobial susceptibility testing

Antimicrob Agents Chemother. 2007 Sep;51(9):3378-80. doi: 10.1128/AAC.00496-07. Epub 2007 Jun 18.

Authors

Olivier Lortholary¹, Eric Dannaoui, Dorothée Raoux, Damien Hoinard, Annick Datry, André Paugam, Jean-Louis Poirot, Claire Lacroix, Françoise Dromer; YEASTS Group

Affiliation

¹ Centre National de Référence Mycologie et Antifongiques, Unité de Mycologie Moléculaire, CNRS URA3012, Institut Pasteur, 25 rue du Dr. Roux, 75724 Paris Cedex 15, France. [email protected]

Abstract

The posaconazole MIC(90) for 1,903 yeast isolates from France was 1 microg/ml (range, < or =0.015 to 8 microg/ml). Ninety percent of isolates with fluconazole MICs of > or =8 microg/ml (n = 509) and 90% of those with voriconazole MICs of > or =2 microg/ml (n = 80) were inhibited by 2 and 8 microg/ml of posaconazole, respectively.

MeSH terms

Antifungal Agents / pharmacology*
Fluconazole / pharmacology
France / epidemiology
Humans
Microbial Sensitivity Tests
Mycoses / epidemiology*
Mycoses / genetics*
Pyrimidines / pharmacology
Triazoles / pharmacology*
Voriconazole
Yeasts / drug effects*

Substances

Antifungal Agents
Pyrimidines
Triazoles
posaconazole
Fluconazole
Voriconazole